

Minireview Article**ROCK INHIBITORS: FUTURE OF ANTI-GLAUCOMA MEDICATION???**

Abstract:

Glaucoma constitutes the major burden of irreversible blindness worldwide as of today. All the modalities of treatment are focussed on lowering intra ocular pressure, from medical to surgical. With the advent of new drugs, drug compliance has increased among the patients but still is the most worrisome problem for doctors. Rho kinase inhibitors (ROCK Inhibitors) modulate changes in the actin cytoskeleton and cellular motility of the trabecular meshwork, Schlemm's canal, and ciliary muscle may comprise a potential new class of ocular hypotensive drugs that enhance aqueous drainage. Being still under trials, hopes are on that these could revolutionise Glaucoma therapy.

INTRODUCTION

Glaucoma is a leading cause of blindness in the world, contributing significantly to disease burden. (1) Unlimited health resources are spent on glaucoma management. Therapeutic strategies vary widely from heavy duty drugs requiring life-long compliance to diverse surgical options with or without shunt devices/ antifibrinolytic agents/ laser. In the last decades, the therapy of glaucoma has largely shifted from surgery to medical treatment thanks to the introduction of strongly effective single and fixed combinations. This clinical scenario may dramatically change in the future thanks to the progresses in biochemistry, genetics and drug delivery technology. Market is huge and so is the niche for development of new agents. Newer agents are desired which can offer not only greater improved efficacy but

24 also reduced intolerance, which is emerging as a leading cause of poor adherence, or non-
25 compliance as is often referred, to topical anti glaucoma therapy (2)

26

27 **CURRENT TRENDS**


28 Abnormally high resistance to aqueous humor drainage through the trabecular meshwork and
29 Schlemm's canal is highly implicated as cause for development of primary open-angle
30 glaucoma. Current anti glaucoma treatments are directed towards lowering intraocular
31 pressure (IOP) which is the main modifiable risk factor for glaucoma. Currently, the five
32 FDA established (3) pharmacologic classes of IOP-lowering drugs are A-adrenergic agonists
33 (e.g. brimonidine); β -adrenergic blockers (e.g. timolol); carbonic anhydrase inhibitors (e.g.
34 dorzolamide); cholinergic agonists (e.g. pilocarpine, carbachol); and prostaglandin analogues
35 (e.g. latanoprost, travoprost, bimatoprost). Prostaglandins are currently the most prescribed
36 glaucoma treatment world. These reduce IOP by increased aqueous outflow, and have not
37 only good potency but also improved adherence profile. The Rho kinase (ROCK) inhibitors,
38 currently under Phase II trials, are emerging as the new class of antiglaucoma drugs.

39

40 **MECHANISM OF ACTION**

41 These act specifically at the trabecular meshwork which has been identified as the prime site
42 of aqueous outflow resistance. These target cells in the trabecular meshwork to enhance
43 aqueous humor outflow. Contractility of the actomyosin system in the trabecular cells or
44 inner wall endothelium of Schlemm's canal is an important factor in the regulation of outflow
45 resistance. Numerous studies indicate that dynamics of the trabecular meshwork cytoskeleton
46 may be involved in the regulation of aqueous humor outflow. Reduction of outflow resistance
47 induced by cytoskeletal agents acting directly on the trabecular meshwork and Schlemm's
48 canal of glaucomatous eyes may mimic the normal physiological function(4). The Rho family

of small guanosine triphosphatases (GTPases) has a central role in these cellular processes, particularly those involving actin cytoskeleton assembly, actin-myosin mediated cell contraction and motility (5)(6). ROCK (Rho-associated coiled coil-forming protein kinase) is a downstream effector of Rho factor in the Rho-dependent signal transduction pathway (7). Thus, specific inhibitors of ROCK, that modulate changes in the actin cytoskeleton and cellular motility of the trabecular meshwork, Schlemm's canal, and ciliary muscle may comprise a potential new class of ocular hypotensive drugs that enhance aqueous drainage (8)(9)(10). ROCK inhibitors may lower resistance to aqueous outflow by activities that include decreasing myosin light-chain phosphorylation, which leads to cellular relaxation in human trabecular meshwork and Schlemm's canal cells.



59

60 Fig 1. ROCK protein function.

61 Since glaucoma is also age-related, it's not surprising that clinical data supports a role for
 62 Rho-kinase in this disease. Zhang et al demonstrated that sustained activation of Rho-
 63 GTPase signalling in the aqueous humor outflow pathway increases resistance to outflow
 64 through the trabecular meshwork, by influencing the actomyosin assembly cell adhesive
 65 interaction and expression of extracellular matrix protein and cytokine in trabecular

66 meshwork cells. (11) In addition, levels of Rho-GTPase agonists, including endothelial 1 and
67 TGF-beta, have been reported to be elevated in the aqueous humor of glaucomatous patients.
68 (12)(13)

69 ANIMAL STUDIES

70 To be able to explore the role of these Rho-kinase inhibitors for glaucoma treatment in
71 humans, various trials are underway (14). Animal model testing is showing vast potential.
72 Four different mechanisms have been described. (15-24)

73 **Firstly**, Rho-kinase inhibitors may be able to increase aqueous outflow by relaxing
74 trabecular meshwork tissue. Studies have demonstrated that selective Rho-kinase inhibitors
75 reduce IOP and increase outflow facility by altering the behaviour of trabecular meshwork
76 cells and relaxing ciliary muscle in bovine and human tissue. (15)(16).

77 **Secondly**, these also work by improving blood flow to the optic nerve. Altered optic nerve
78 perfusion, due either to vasospasm or altered hemodynamics, is believed to play a role in the
79 pathophysiology of certain types of glaucoma, especially normal tension glaucoma, and it is
80 believed that some of these glaucoma patients may have altered blood perfusion in the rest of
81 the body as well. (17)(18) These agents not only improve optic nerve perfusion but also
82 improve cerebral and coronary perfusion. (19)(20)

83 **Thirdly**, Rho-kinase inhibitors may provide neuroprotection of healthy ganglion cells.
84 Animal studies have shown the involvement of Rho-kinase in induced neurotoxicity, and that
85 Rho-kinase inhibition at the cell body is neuroprotective and overcomes growth
86 inhibition.(21)(22) In addition, animal studies have shown an increase in retinal ganglion cell
87 survival with Rho-kinase inhibitors.(23)

Fourthly, Rho-kinase inhibitors may aid us in treating glaucoma as an antifibrotic agent in glaucoma surgery. One of the main reasons for failure of glaucoma surgery is scarring. Although the use of antimetabolites (5FU or mitomycin C) has decreased the incidence of glaucoma surgery failure, it's associated with a higher incidence of bleb-related complications. In contrast Honjo M, et al; demonstrated that topical use of Y 27632 (a Rho-kinase inhibitor) is associated with reduced subconjunctival scarring in rabbits after filtration surgery and that it was safe and well-tolerated. (24)

ROUTES OF ADMINISTRATION

Various routes of administration have been studied in rabbits and IOP was seen to fall within 30 minutes, with the effect lasting upto 12 hours in topical, intravitreal as well as intracameral injections. (15) . Safety and efficacy of topical route in humans has also been demonstrated by a Phase I clinical trial with SNJ-1656, a selective Rho-kinase inhibitor, used at different concentrations. (25)

DRUG	ORGANIZATION	CLINICAL TRIAL PHASE	NOTES
AR-12286	Aerie	PII	Rho kinase inhibitor
INS-117548	INSPIRE	P I	Rho kinase inhibitor
K-115	Kowa	PII	Rho kinase inhibitor
Y-39983; SNJ-1656; RKI-983	Senju/Novartis	PII	Rho kinase inhibitor

101

102 TABLE 1- RHO KINASE INHIBITORS UNDER CLINICAL TRIALS

103

104 **ONGOING CLINICAL TRIALS**

105 ROCK inhibitors that are currently in clinical trials for glaucoma or ocular hypertension

106 include AR-12286 (Phase II, Aerie Pharmaceuticals) and K-115 (Phase II, Kowa

107 Pharmaceutical). Other ROCK inhibitors Y-39983/SNJ-1656/ RKI-983 (Phase II, Senju and

108 Novartis Pharmaceuticals) and INS-117548 (Phase I, Inspire Pharmaceuticals) are still under

109 development, but have encountered efficacy and tolerability.

110 **CHALLENGES??**

111 DE-104 (Phase I/II, Santen Pharmaceuticals and Ube Industries) development was

112 discontinued in late 2010 after its trial failed to meet the primary endpoint. (5)

113

114 **ROLE OF ROCK INHIBITORS OUTSIDE THE EYE**

115 Recent research has shown that ROCK signalling plays an important role in many diseases

116 including diabetes, neurodegenerative diseases, pulmonary hypertension (26) and cancer. It

117 has been shown to be involved in causing tissue thickening and stiffening around tumours in

118 a mouse model of skin cancer, principally by increasing the amount of collagen in the tissue

119 around the tumour. (27). For example, such drugs could potentially prevent cancer from

120 spreading by blocking cell migration, stopping cancer cells from spreading into neighbouring

121 tissue. (28)

122 **PIT FALLS**

Rho kinase inhibitors seem to have a promising role in glaucoma management. The one notable problem with using Rho-kinase inhibitors to treat glaucoma at this point is that selective Rho-kinase inhibitors are not available. Being able to target only the desired cells may be crucial, as increasing the concentration of a non-specific Rho-kinase inhibitor could have undesirable consequences. Given our limited knowledge about the multitude of biochemical systems and interactions taking place inside the eye, it's impossible to know what the exact effect of increasing the level of non-specific Rho-kinase inhibitors might be, but a molecule designed to affect only trabecular meshwork tissue would be a safer alternative.

CONCLUSION

ROCK Inhibitors, though still in their research phase, may emerge as a new therapeutic option for glaucoma management and revolutionise both medical and surgical therapy.

REFERENCES

- (1) Varma R, Lee PP, Goldberg I, Kotak S. An assessment of the health and economic burden of glaucoma. *AmJ Ophthalmol*. 2011 Oct; 152(4):515-22 doi: 10.1016/j.ajo.2011.06.004
- (2) Lacey J, Cate H, Broadway DC. Barriers to adherence with glaucoma medications: a qualitative research study. *Eye (Lond)*. 2009 Apr;23(4):924-32. doi: 10.1038/eye.2008.103. Epub 2008 Apr 25.
- (3) Weinreb RN, Kaufman PL. The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium. *Invest Ophthalmol Vis Sci*. 2009;50(4):1497–1505.

- 145 (4) .Baohu Tian, B'Ann T. Gabelt, Benjamin Geiger, Paul L. Kaufman, The Role of the
146 Actomyosin System in Regulating Trabecular Fluid Outflow. *Exp Eye Res*. 2009 April ;
147 88(4): 713.
- 148 (5). Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. *Nat Rev Mol Cell*
149 *Biol*. 2003;4(6):446–456.
- 150 (6). Hall A. Rho GTPases and the control of cell behaviour. *Biochem Soc Trans*. 2005;33(Pt
151 5):891–895.
- 152 (7) Olson MF. Applications for ROCK kinase inhibition. *Curr Opin Cell Biol*.
153 2008;20(2):242–248.
- 154 (8) Involvement of phosphorylation of myosin phosphatase by ROCK in trabecular
155 meshwork and ciliary muscle contraction. *Biochem Biophys Res Commun*. 2001;288(2):296–
156 300.
- 157 (9) Nakajima E, Nakajima T, Minagawa Y, Shearer TR, Azuma M. Contribution of ROCK in
158 contraction of trabecular meshwork: proposed mechanism for regulating aqueous outflow in
159 monkey and human eyes. *J Pharm Sci*. 2005;94(4):701–708.
- 160 (10) Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the
161 treatment of glaucoma. *Bio Drugs*. 2007;21(3):167–177.
- 162 (11) Zhang M, Maddala R, Rao PV. Novel molecular insights into RhoA GTPase-induced
163 resistance to aqueous humor outflow through the trabecular meshwork. *Am J Physiol Cell*
164 *Physiol* 2008;295:5:C1057-70.
- 165 (12) Noske W, Hensen J, Wiederholt M. Endothelin-like immunoreactivity in aqueous
166 humor of patients with primary open-angle glaucoma and cataract. *Graefes Arch Clin Exp*
167 *Ophthalmol*. 1997;235:9:551-2.
- 168 (13).Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains
169 an increased level of TGF-beta 2. *Exp Eye Res* 1994;59:6:723-7

- 170 (14) Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. *Nat Rev Mol*
171 *Cell Biol.* 2003;4(6):446–456.
- 172 (15) 5. Honjo M, Tanihara H, Inatani M, Kido N, Sawamura T, Yue BY, Narumiya S, Honda
173 Y. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and
174 outflow facility. *Invest Ophthalmol Vis Sci* 2001;42:1:137-44.
- 175 (16). Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility
176 by the Rho kinase-specific inhibitor Y-27632. *Invest Ophthalmol Vis Sci* 2001;425:1029-37.
- 177 (17). Delaney Y, Walshe TE, O'Brien C Delaney Y, et al. Vasospasm in glaucoma: Clinical
178 and laboratory aspects. *Optom Vis Sci* 2006;83:7:406-414.
- 179 (18). Grieshaber MC, Flammer J. Blood flow in glaucoma. *Curr Opin Ophthalmol*
180 2005;16:2:79-83.
- 181 (19). Chrissobolis, S. et al. Evidence that estrogen suppresses Rho Kinase function in the
182 cerebral circulation in vivo. *Stroke* 2004; 35:2200-2205
- 183 (20). Kandabashi, T et al. Evidence for protein kinase C-mediated activation of Rho-kinase in
184 a porcine model of coronary artery spasm. *Arterioscler Thromb Vasc Biol* 2003;23:12:2209-
185 2214
- 186 (21) Kitaoka Y, et al. Involvement of RhoA and possible neuroprotective effect of fasudil, a
187 Rho-kinase inhibitor, in NMDA-induced neurotoxicity in the rat retina. *Brain Res*
188 2004;1018:1:111-8.
- 189 (22) Bertrand J, Winton MJ, Rodriguez-Hernandez N, Campenot RB, McKerracher L.
190 Application of Rho antagonist to neuronal cell bodies promotes neurite growth in
191 compartmented cultures and regeneration of retinal ganglion cell axons in the optic nerve of
192 adult rats. *J Neurosci* 2005;25:5:1113-21.

- 193 (23). Bertrand J, Di Polo A, McKerracher L. Enhanced survival and regeneration of
194 axotomized retinal neurons by repeated delivery of cell permeable C3-like Rho antagonists.
195 Neurobiology Dis 2007;25:1:65-72
- 196 (24). Honjo M, et al., Potential Role of Rho-Associated Protein Kinase Inhibitor Y27632 in
197 glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2007;48:12:5549-5557
- 198 (25) Tanihara H, et al. Intraocular pressure-lowering effects and safety of topical
199 administration of selective ROCK inhibition, SNJ-1656 in healthy volunteers. Arch
200 Ophthalmol 2008;126:3:309-15.
- 201 (26) Dahal BK, Kosanovic D *et al.* (2010). "Therapeutic efficacy of azaindole-1 in
202 experimental pulmonary hypertension". *European Respiratory Journal* 36(4):808-18 (4):
203 808–18
- 204 (27)Samuel, MS.; Lopez, JI.; McGhee, EJ.; Croft, DR.; Strachan, D.; Timpson, P.; Munro, J.;
205 Schröder, E. et al. (Jun 2011). "Actomyosin-mediated cellular tension drives increased tissue
206 stiffness and β -catenin activation to induce interfollicular epidermal hyperplasia and tumor
207 growth".
- 208 (28) Hahmann C, Schroeter T (2010). "Rho-kinase inhibitors as therapeutics: from pan
209 inhibition to isoform selectivity". *Cell Mol Life Sci* 67 (2): 171–7